1 week Ago By ABMN Staff
Shares of Humacyte, Inc. ( NASDAQ:HUMA – Get Free Report ) have been given a consensus rating of “Buy” by the eight brokerages that are presently covering the stock, Marketbeat.com reports.
One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.71.
Several equities analysts have commented on HUMA shares. HC Wainwright reissued a “buy” rating and set a $15.00 target price (up previously from $12.
00) on shares of Humacyte in a research note on Friday. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th.
Benchmark increased their price target on Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday.
EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $13.
00 price objective on shares of Humacyte in a report on Friday, September 20th. View Our Latest Report on HUMA Humacyte Price Performance Insider Transactions at Humacyte In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of the business’s stock in a transaction dated Monday, November 18th.
The stock was sold at an average price of $4.44, for a total transaction of $3,601,603.68.
Following the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. The trade was a 25.
11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink . Also, Director Brady W.
Dougan sold 427,459 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.
06. Following the completion of the transaction, the director now owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02.
The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders sold a total of 1,500,000 shares of company stock valued at $6,606,799 in the last three months. 11.20% of the stock is currently owned by corporate insiders.
Institutional Trading of Humacyte Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in shares of Humacyte by 693.0% in the second quarter.
Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the period. State Street Corp boosted its position in Humacyte by 66.1% during the 3rd quarter.
State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after acquiring an additional 1,895,529 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Humacyte during the 3rd quarter worth about $596,000. Thrivent Financial for Lutherans purchased a new position in Humacyte during the 3rd quarter valued at about $712,000.
Finally, Millennium Management LLC increased its holdings in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares during the period.
44.71% of the stock is owned by institutional investors and hedge funds. Humacyte Company Profile ( Get Free Report Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. Recommended Stories Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter .
.
